An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ASPIRE
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 29 Jun 2016 This trial was completed in Finland, Bulgaria, Slovakia and Spain according to the European Clinical Trials Database.
- 14 Aug 2013 Planned number of patients changed from 550 to 708 as reported by ClinicalTrials.gov.
- 14 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.